Head-To-Head Contrast: Medpace (NASDAQ:MEDP) and Selectis Health (OTCMKTS:GBCS)

Medpace (NASDAQ:MEDP) and Selectis Health (OTCMKTS:GBCS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.

Institutional and Insider Ownership

78.0% of Medpace shares are owned by institutional investors. 20.5% of Medpace shares are owned by company insiders. Comparatively, 15.2% of Selectis Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Medpace and Selectis Health”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53 billion	6.30	$451.12 million	$17.06	33.47
Selectis Health	$41.44 million	0.41	-$1.02 million	($0.34)	-16.18

Medpace has higher revenue and earnings than Selectis Health. Selectis Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Medpace and Selectis Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0	11	2	0	2.15
Selectis Health	0	0	0	0	0.00

Medpace currently has a consensus price target of $584.18, indicating a potential upside of 2.31%. Given Medpace’s stronger consensus rating and higher possible upside, analysts plainly believe Medpace is more favorable than Selectis Health.

Profitability

This table compares Medpace and Selectis Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Selectis Health	-2.45%	N/A	-3.03%

Volatility & Risk

Medpace has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Selectis Health has a beta of -1.07, suggesting that its stock price is 207% less volatile than the S&P 500.

Summary

Medpace beats Selectis Health on 14 of the 14 factors compared between the two stocks.

About Medpace

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

About Selectis Health

Selectis Health owns and/or operates healthcare facilities in Arkansas, Georgia, Ohio, and Oklahoma, providing a wide array of living services, speech, occupational, physical therapies, social services, and other rehabilitation and healthcare services. Selectis focuses on building strategic relationships with local communities in which its partnership can improve the quality of care for facility residents. With its focused growth strategy, Selectis intends to deepen its American Southcentral and Southeastern market presence to better serve the aging population along a full continuum of care.